|
 |
AgalsidaseThis page contains recent news articles, when available, and an overview of Agalsidase but does not offer medical advice. You should contact your physician with regard to any health issues or concerns....excluding UK and Republic of Ireland) REPLAGAL(R) (agalsidase alfa) VYVANSE(TM) (lisdexamfetamine dimesylate) XAGRID(TM) (anagrelide hydrochloride) MarketWatch Genzyme Reports Strong Second-Quarter Growth - Jul 23, 2008 Sales of Fabrazyme(R) (agalsidase beta) grew 21 percent, rising to $126.6 million from $104.3 million. Sales of Aldurazyme(R) (laronidase) increased 33 FOXBusiness Shire will deutsches Biotech Jerini für 328 Mio € - Jul 8, 2008 ...erleichtern soll, analog zur erfolgreichen Strategie für die aktuellen Orphan-Arzneimittel Elaprase (Idursulfase) und Replagal (Agalsidase alfa). Chemiereport, Genzyme Reports Strong First-Quarter Growth - 23 Apr 2008 Sales of Fabrazyme(R) (agalsidase beta) grew 16 percent in the quarter, rising to $116.5 million from $100.7 million in the first quarter last year. PR Newswire (press release), Enzyme replacement improves cardiomyopathy in Anderson-Fabry disease - Feb 18, 2008 Enzyme replacement with agalsidase alfa results in regression of hypertrophic cardiomyopathy in patients with Anderson-Fabry disease, Medicexchange, Genzyme Corp swings into the black for fourth quarter - Feb 14, 2008 ...driven by sales of Gaucher disease treatment Cerezyme (imiglucerase), up 15% to $301 million and Fabry disease drug Fabrazyme (agalsidase beta), Pharma Times (subscription), Vyvanse confounds analysts as net income soars at Shire - Feb 22, 2008 Replagal (agalsidase alfa), for the treatment of Fabry disease, contributed $38.9 million to the coffers, up 25%, while the ulcerative colitis therapy Pharma Times (subscription), Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year - Feb 14, 2008 Sales of Fabrazyme® (agalsidase beta) are expected to reach $495-$505 million this year, compared with $424 million in 2007. The European Commission has Lifescience-online, Samaritan to Launch REPLAGAL® for Fabry Disease in Greece and Cyprus - Feb 5, 2008 Shire Human Genetic Therapies AB to launch and sell REPLAGAL(r) (agalsidase alfa), a European approved drug, for Fabry Disease, in Greece and Cyprus. Free press releases (press release), Genzyme: following the RNA therapy trend - Jan 12, 2008 Genzyme's biggest selling product, Fabrazyme (agalsidase) for Fabry disease; and Myozyme (alglucosidase alfa), which is used to treat Pompe disease, Pharmaceutical Business Review Genzyme Reports 21 Percent Increase in Fourth-Quarter Revenue - Jan 8, 2008 Fourth-quarter sales of Fabrazyme(R) (agalsidase beta) were $114 million, up 18 percent from $97 million in the same quarter a year ago. FOX News TKT Forms European Company to Market Niche Protein Products -TKT ... - Jan 17, 2008 TKT also announced today that the Committee of Orphan Medicinal Products has recommended Replagal(TM) (agalsidase alfa) for orphan drug designation in news aktuell (Pressemitteilung), High-profit products old and new keep Genzyme on the up - Jan 9, 2008 ...was up 15% to $301 million, while fourth-quarter sales of Fabry disease therapy Fabrazyme (agalsidase beta) were up 18% to $114 million. Pharma Times (subscription), Isis and Genzyme sign $1.9 billion cholesterol alliance - Jan 8, 2008 ...such as the Gaucher disease treatment Cerezyme (imiglucerase), and Fabry disease drug Fabrazyme (agalsidase beta), that makes it an attractive partner Pharma Times (subscription), Research and Markets: Shire Spends over Us$8 Billion on ... - Nov 29, 2007 Vyvanse (lisdexamphetamine dimesylate) Gastrointestinal Pentasa (mesalamine) Human Genetic Therapies Replagal (agalsidase) Elaprase (idursulfase) Renal Reuters Shire goes from strength to strength with its ADHD drugs - Nov 2, 2007 Replagal (agalsidase alfa), for the treatment of Fabry disease, contributed $40.7 million to the coffers, up 26%, while the ulcerative colitis therapy Pharma Times (subscription), LSD Deal Brings Amicus $50M Now, $390M Later - Nov 8, 2007 In the third quarter of 2007, Genzyme's Fabry disease drug Fabrazyme (agalsidase beta) brought in $104.6 million, while its Gaucher disease drug Cerezyme BioWorld Online, Genzyme Reports Strong Earnings Growth in Third Quarter - Oct 24, 2007 Sales of Fabrazyme(R) (agalsidase beta) increased 12 percent to $104.6 million, compared with $93.2 million in the same quarter last year. CNNMoney.com Shire signs rare disease drug licensing deal with Amicus - Nov 9, 2007 ...which includes Replagal (agalsidase alfa) for the treatment of Fabry disease and Elaprase (idursulfase) for Hunter syndrome. The company also has GA-GCB Checkbiotech.org (press release), Genzyme confident of 20% earnings growth for next five years - Oct 25, 2007 ...driven by sales of Gaucher disease treatment Cerezyme (imiglucerase), up 13% to $286.1 million and Fabry disease drug Fabrazyme (agalsidase beta), Pharma Times (subscription), FOLD: Sees 52-Week High on Tuesday After Positive Ph I Study for ... - Oct 23, 2007 Genzyme, the early pioneer in this area, has developed Fabrazyme(R) (agalsidase beta) to replace the missing enzyme in patients with Fabry disease. Trading Markets (press release), Further Upgrade to 2007 Financial Guidance Based on Strong Revenue ... - Nov 1, 2007 ...(UK and Republic of Ireland) REMINYL XL(TM) (galantamine hydrobromide) (UK and Republic of Ireland) REPLAGAL(R) (agalsidase alfa) SOLARAZE(R) (3%, PR Newswire (press release), Genzyme Receives Approval to Market Elaprase(R) in Japan - Oct 4, 2007 The company also markets Cerezyme(R) (imiglucerase for injection) for Type 1 Gaucher disease; Fabrazyme(R) (agalsidase beta) for Fabry disease; CNNMoney.com Genzyme Begins Major Expansion of Boston Manufacturing Facility - Sep 18, 2007 Three are manufactured there: Cerezyme; Fabrazyme(R) (agalsidase beta) for Fabry disease; and Myozyme(R) (alglucosidase alfa) for Pompe disease. CNNMoney.com Genzyme expands flagship facility - Sep 18, 2007 Since then a further four products have been introduced to the facility including Fabrazyme (agalsidase beta) for Fabry disease, and Myozyme (alglucosidase US-PharmaTechnologist.com, Paladin Expands Distribution Agreement with Shire HGT to Include ... - Aug 8, 2007 Under the new agreement, Paladin will be distributing ELAPRASE(TM) (idursulfase) for Hunter syndrome in addition to REPLAGAL® (agalsidase alfa) for Fabry Earthtimes.org Combination Therapy Benefits Fabry Disease Patients - 06 Aug 2007 Renal and Urology News,...by Jody A. Charnow Combining an ACE inhibitor (ACEI) and angiotensin-receptor blocker (ARB) with enzyme replacement therapy using agalsidase-beta (Fabrazyme Combination Therapy Halts Kidney Function Loss in Genetic Disease - Jul 26, 2007 MedPage Today,Adding agalsidase-β (Fabrazyme) to an ACE inhibitor and an angiotensin receptor blocker (ARB) produced a sustained reduction in proteinuria in six patients Combination Therapy Stops Loss of Kidney Function - Jul 30, 2007 Genomics & Proteomics,...an angiotensin-receptor blocker (ARB), added to enzyme replacement therapy (ERT) with agalsidase-beta (Fabrazyme, Genzyme Corporation, Cambridge, Mass. Combination Therapy Stops Loss Of Kidney Function In Rare Genetic ... - Jul 27, 2007 Science Daily (press release)Reduction of Proteinuria in Patients Receiving Enzyme Replacement Therapy with Agalsidase-Beta" will be available online beginning on Wednesday, Genzyme Reports Significant Earnings Growth in Second Quarter - Jul 25, 2007 CNNMoney.comSales of Fabrazyme(R) (agalsidase beta) increased 17 percent to $104.3 million, compared with $89.0 million in the same quarter last year. Early intervention with (pr)Fabrazyme(R) key to preventing renal ... - Jun 15, 2007 PipelineReview.com (press release),The 54-month phase III, open-label extension study in Fabry disease demonstrated that early intervention with (pr)Fabrazyme(R) (agalsidase beta) preserves Genzyme - Honor Given by President of the United States for ... - Jun 19, 2007 Oxfordshire Bioscience Network (press release),...for Gaucher disease, Fabrazyme® (agalsidase beta) for Fabry disease, Aldurazyme® (laronidase), developed with partner BioMarin Pharmaceutical for MPS I, Genzyme's combination gene therapy shows potential for CNS disease - 25 May 2007 DrugResearcher.com,Gaucher disease, Fabrazyme (agalsidase beta) for Fabry disease, Aldurazyme (laronidase) for MPS I and Myozyme (alglucosidase alfa) for Pompe disease. Shire Human Genetic Therapies AB Signs Exclusive Marketing and ... - May 22, 2007 Primenewswire (press release),Shire Human Genetic Therapies AB to launch and sell REPLAGAL(r) (agalsidase alfa), a European approved drug, for Fabry Disease, in Greece and Cyprus. Shire storms ahead with strong sales across the board - 26 Apr 2007 Pharma Times (subscription),Replagal (agalsidase alfa), for the treatment of Fabry disease, contributed $32.5 million to the coffers, up 26%, while the ulcerative colitis therapy Genzyme Reports Significant Revenue and Earnings Growth in First ... - 26 Apr 2007 WebWire (press release),Genzyme’s three other treatments for lysosomal storage disorders showed continued strength in the first quarter: Sales of Fabrazyme® (agalsidase beta) for SHIRE PLC - 1st Quarter Results - Apr 25, 2007 PR-Inside.com (Pressemitteilung),REPLAGAL® (agalsidase alfa) - Fabry disease * REPLAGAL was launched in Japan through Shire's partner Dainippon Sumitomo Pharma Co., Ltd on February 15, Enzyme Replacement in Fabry Disease: The Essence Is in the Kidney - Jan 16, 2007 Annals of Internal MedicineBoth preparations are used in most countries, but the US Food and Drug Administration (FDA) approved only agalsidase beta. They approved it on an expedited Largest-ever Fabry study shows earlier treatment with (Pr ... - Jan 17, 2007 PipelineReview.com (press release),The study, entitled Agalsidase-Beta Therapy for Advanced Fabry Disease, has shown that early treatment with the enzyme replacement therapy Fabrazyme at 1 Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude ... - Jan 10, 2007 Oxfordshire Bioscience Network (press release),Fourth-quarter sales of Fabrazyme® (agalsidase beta) for Fabry disease were $96 million, up 18 percent from $82 million in the same quarter a year ago. First Therapy Ever Approved in Canada for Ultra-Rare Form of ... - Dec 8, 2006 DG NewsGenzyme has developed PrFabrazyme® (agalsidase beta) for Fabry disease, PrCerezyme® (imiglucerase) for Type 1 and Type 3 Gaucher disease and, : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |